Faculty of Pharmacy
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/17
Browse
47 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Design and biological response of doxycycline loaded chitosan microparticles for periodontal disease treatment(Elsevier BV, 2018-04-15); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Rational development of nanomedicines for molecular targeting in periodontal disease(Elsevier BV, 2018-09); ; Recent advances in understanding the etiology and pathogenesis of periodontal disease and polymicrobial synergy in the dysbiotic oral microbial community endorsed novel therapeutic targets and assured further improvement in periodontal disease treatment. Moreover, understanding of the events at the molecular level inspired the researchers to alleviate the stress from the disease by applying the bottom-up approach and delivering the drugs at the site of action, using nanoscale medicines. This review is focused on promising strategies for rational design of nanopaharmaceuticals for periodontal disease treatment based on novel therapeutic targets and the potential of advanced concepts for inflammation cascade targeting. Due to their size, nanomedicines are capable to interact with the elements of the immune system through cell receptor binding and to subsequently influence specific intracellular signaling pathways activation. They might also interfere with different signaling molecules continuously involved in the disease progression, in order to abolish cell activation and block the production of proinflammatory substances. Different biomacromolecules can be trafficked to the site of action using nanomedicines for gene targeting: i) decoy oligodeoxynucleotide (ODN) for suppression of NF-κB transcription activity, ii) DNA therapeutics for modulation of cell inflammatory response and iii) siRNA for cytokine production silencing. However, despite the potential of the nanotechnology for improvement of periodontal disease treatment, the translation of nano-drug delivery systems to clinical therapy is hindered by the lack of standard procedures for proper safety and efficacy profile evaluation. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, MDM2309 (rs2279744) polymorphisms and risk for HPV persistence and cervical intraepithelial lesions and cervical cancer development in Macedonian women(2018)SotirijaDuvlis, Drage Dabeski, Ljube Ivkovski, Marija Hiljadnikova-Bajro, Dijana Plaseska Karanfilska - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Association of p53Pro72Arg (rs1042522) and MDM2309 (rs2279744) polymorphisms with risk for cervical intraepthelial lesions and cervical cancer development in Macedonian women(2016) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Distribution of the most Common Genetic Variants Associated with a Variable Drug Response in the Population of the Republic of Macedonia(2014-12) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A novel germline MLH1 mutation causing Lynch Syndrome in patients from the Republic of Macedonia(2012-10) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, A new case with 10q23 interstitial deletion encompassing both PTEN and BMPR1A narrows the genetic region deleted in juvenile polyposis syndrome(Springer Science and Business Media LLC, 2012-09-21) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer(Elsevier BV, 2012-04); Kapedanovska Nestorovska, Aleksandra - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Biomolecular laboratory markers in cancer management(2017)The laboratory analysis is a compulsory supplement to clinical evaluation in making decisions upon diagnosis and treatment of cancer, one of the leading causes of death worldwide. The traditional biochemical laboratory protocols employed in diagnosis, prognosis and monitoring of malignant diseases include testing of soluble macromolecules as tumor markers and certain common parameters corresponding to the specific type of malignancy, but their limited reliability urges the necessity of identifying new biomarkers with higher specificity, sensitivity and predictability. Biomolecular/genetic testing is an emerging field within the scope of laboratory analysis with high clinical potential based on the assumption that revealing the genetic profile unique to each individual cancer may help predict the prognosis and select an appropriate treatment to target the changes in the specific tumor. This work reviews the currently available genomic laboratory tests and highlights their clinical and scientific relevance. Implication of aberrant transcripts BCR-ABL and PML-RAR for the management of leukemias, detection of genetic and epigenetic aberrations associated with familial cancer syndromes (MMR gene defects in Lynch Syndrome), pharmacogenetic assays for HER2, EGFR, ALK, KRAS, BRAF, UGT1A1 testing for selection of appropriate most efficient and least toxic treatment of particular cancer types will be addressed, along with novel, recently identified markers with anticipated clinical impact. The rapid development of high throughput technologies shifting singleplex towards multiplex testing, such as the next generation sequencing paired with bioinformatics which enable fast and affordable sequencing of the entire genome of an individual, will inevitably empower accelerated establishment of new biomolecular markers associated with the process of cancer initiation and progression. A comparative overview of the contemporary methodologies will be presented in the lecture. Multidisciplinary efforts should be made to implement the benefits from the technological advancement in the scientific process of new biomarker identification and translation of the research results into clinical practice, in order to provide best treatment for cancer patients in accordance with the principles of the precision medicine. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Pharmacogenetic testing in optimization of treatment with statins(2018-10)Statins are a class of drugs that have been widely prescribed nowadays for treating hypercholesterolemia and thus prevent the risk of atherosclerotic cardiovascular events and consecutive mortality. Unfortunate ly, the patient’s compliance with treatment is frequently compromised by the high incidence of adverse effects including hepatotoxicity, myotoxicity, increased risk for diabetes mellitus etc. The expansion of the precision medicine concept in pharmacology has introduced pharmacogenetic testing as a potential predictive strategy in statins pharmacotherapy. A thorough literature survey was performed using the PubMed database on the published data in English language in the period 2000-2017, regarding genotype-phenotype associations in statin-induced toxicity, identifying a growing body of evidence supporting the need for pharmacogenetic approach in treatment with statins. Polymorphisms in the genes coding for the CYP450 enzymes: CYP2D6, DYP2D9, CYP3A4 and drug transporter genes like ABCB1, ABCG2 and SLCO1B1 appear to be responsible for the variable re sponse and toxicity of statins. But, many studies highlight the importance of drug interactions and epi genetics in modifying the response towards this class of drugs metabolized via pathways shared by the majority of pharmaceutical agents. With the rapid development of molecular techniques accompanied by a dramatic cost reduction in genetic testing, it can be easily anticipated that pharmacogenetic patient profiling will soon become standard of care in designing the optimal statin treatment either as a monotherapy or in combination with other phar maceuticals.